Insilico Medicine
Insilico Medicine and Menarini Group’s Stemline Therapeutics Announce Second Exclusive Licensing Agreement for AI-Discovered Oncology Drug Candidate
Insilico Medicine, Menarini Group, Stemline Therapeutics, AI-generated cancer drug, Oncology drug candidate, Licensing agreement, $550 million deal